The Centers for Medicare and Medicaid Services is famous for auditing the two big government health programs that it runs. But CMS faces audits also. The inspector general's office within HHS is one of the groups that keeps a close eye on CMS. And, like an internal family feud, criticism from within HHS can often be the most frank and painful. CMS is feeling the pain from a review of pharmacy acquisiton costs under Part D;' there is more coming.
Cole Werble
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.
